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Take-home message 
Ambulatory Oxygen may be cost-effective in improving quality of life in fibrotic lung 
disease. To be more conclusive, we need to understand societal willingness to pay for quality 
of life improvements and whether improvements are sustained. 
Plain language summary 
Interstitial lung disease (ILD) is an umbrella term used to describe a range of lung conditions 
that cause scarring (fibrosis) of the lungs. The conditions are long-term and usually get worse 
with time, with very few treatment options to improve symptoms. ILD can have a big impact 
on quality of life for patients, making them short of breath and affecting their ability to carry 
out usual activities. A recent clinical study carried out in the UK found that using 
“ambulatory” oxygen treatment given to help people with ILD when they go about their day-
to-day activities for a two-week period improved their quality of life. Using data from this 
study, we find that ambulatory oxygen may be good value for money for the National Health 
Service (NHS). However, before we can be certain about this, we need to understand whether 
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Fibrotic Interstitial Lung Diseases (ILDs) are chronic and often progressive conditions 
resulting in substantial impact on morbidity, health-related quality of life (HRQoL), and 
health system costs. Ambulatory oxygen (AO) used during routine daily activities could lead 
to improved exercise performance, reduced symptoms and improved mobility in daily life. A 
UK prospective, multicentre, mixed method, randomised controlled crossover trial in patients 
with fibrotic ILD (AmbOx trial: NCT02286063), the first study on AO effects in daily life, 
reported improved HRQoL after two weeks of AO compared to no intervention, when 
measured by the King’s Brief ILD (K-BILD) questionnaire[1-3]. Although AO is used in 
ILD, evidence supporting its health-economic impact is absent. Here, we evaluate the cost-
effectiveness of AO in patients with ILD, using data collected alongside the AmbOx Trial. 
AmbOx included adults with fibrotic ILD with isolated exertional hypoxia[1, 2]. Participants 
(mean age 67.9years; 31% female) were randomised to receive either AO during routine 
activities of daily living (n=41) or no intervention (n=43) first. After a two-week period, the 
groups were crossed over to the alternative. AO for two weeks was associated with a 
significant improvement in total K-BILD score compared to no oxygen (mean difference 
adjusted for treatment order 3.7, 95%CI 1.8 to 5.6). 
For this economic evaluation, data were analysed on a complete case basis (n=74; of the 76 
participants completing AmbOx, 2 had missing K-BILD scores). We estimated resource use 
and costs incurred from a National Health Service (NHS) perspective. Costs of AO were 
based on the number of cylinders used (median 2.75 cylinders per week, range 0-14) [1, 2] 
and assumed use of one nasal cannula per participant [4, 5]. Rental prices for oxygen 
cylinders (£0.25/day), refills (£10.56/refill) and delivery (£16.90/delivery) were not available 
from UK suppliers (commercial in confidence) and so were assumed based on online 
information for an Australian medical gas cylinder company[6]. As AO was not anticipated 
to have any effect on disease progression in the short-term, costs related to any unplanned 
health professional visits or hospital admissions were not included. The mean cost for AO for 
two weeks was estimated to be £91.02 (95%CI £77.83 to £104.21) per participant [costs 
expressed in GBP 2017 (£), after conversion using 1AUD=0.608 GBP). 
We estimated the incremental cost per unit improvement in total K-BILD score, the primary 
trial outcome [1]. A one-point improvement in K-BILD score over a two-week period was 
estimated to cost an additional £25.21 (bootstrapped 95%CI £15.21 to £69.48). Sensitivity 
analyses using the intention to treat cohort (with multiple imputation to adjust for missing 
values) gave a similar incremental cost of £27.38 (95%CI £15.68 to £86.77). Likewise, the 
estimated cost-effectiveness was not substantially impacted if the costs of the intervention 
were changed by up to +/-80% of that assumed in the primary analysis (mean estimated cost 
per unit improvement in K-BILD £14.42 to £46.72 over a two-week period). 
We also undertook post-hoc analyses to estimate the cost-effectiveness of AO in providing a 
benefit based on the number of participants who reported a minimum of an 8 or 4 unit 
improvement in total K-BILD score (these values have been  reported as the minimal 
clinically important difference, MCID[3, 7]), or an improvement in the patient-reported 
global assessment of change in breathlessness and walking ability at the end of each two-
week treatment period, one of the pre-defined major secondary trial outcomes [2]. A 8-unit 
improvement in K-BILD score was reported for 13 (17.6%, NNT 5.85) and a 4-unit 
improvement for 27 (36.5%, NNT 2.81) of participants [2]. Given an incremental cost of 
£91.02 (95%CI £77.83 to £104.21) per person treated for two weeks, it is estimated to cost an 
additional £532.47 (£455.31 to £609.63) to achieve one additional ‘responder’ of at least 8-
units or £255.77 (£218.70 to £292.83) to achieve one additional ‘responder’ of at least 4 units 
on the K-BILD, over a two-week period. 
Data on global assessment of change was available for 76 participants. More participants 
perceived an improvement in their walking ability (51, 67.1%) or breathlessness (52, 68.4%) 
after receiving oxygen as compared to no oxygen (1, 1.3% in each case). This corresponds to 
a number needed to treat of 0.02 for one additional patient to perceive an improvement in 
walking ability or breathlessness, and an estimated incremental cost of £1.82 (£1.56 to £2.08) 
over two weeks to achieve one additional person perceiving an improvement. 
This economic evaluation is the first to examine the cost-effectiveness of AO in fibrotic ILD, 
often a devastating and progressive group of diseases with substantial impact on patients’ 
HRQoL and limited treatment options. Whether or not AO is considered to be of acceptable 
cost-effectiveness depends on society’s (unknown) willingness to pay for an improvement in 
K-BILD score or the global assessment measures. The analysis suggests a much lower 
number needed to treat (and therefore cost for one additional responder) to obtain a perceived 
improvement in breathlessness or walking ability according to the global assessment 
measures, than to achieve an improvement in HRQoL according to the K-BILD. This 
apparent responsiveness for the global assessment of change might be related to the 
comparative bluntness of the single item measure and the possible impact of non-blinding on 
the participants’ self-reported perception of improvement.  
There are limitations associated with our study. Costs for oxygen cylinders were assumed, 
although sensitivity analysis suggests this assumption did not substantially impact findings. 
The AmbOx trial was open label, had a relatively small sample size and a short duration of 
oxygen use (2 weeks) making it challenging to extrapolate the costs or benefits to ILD 
patients in the longer term. It is possible that people using AO would be more likely to access 
long-term oxygen therapy as they become accustomed to the idea of using oxygen, with yet 
unknown benefits and drawbacks. This analysis should be considered as indicative only, until 
data from a larger study with longer follow-up is available to support more conclusive 
assertions. Finally, light weight oxygen cylinders were used for all patients to standardise the 
intervention and to allow for higher oxygen flow rates in patients with more severe exertional 
hypoxia [2], but further studies are needed to assess whether portable oxygen concentrators 
may be more beneficial for the subset with milder ILD.  
We had intended to evaluate cost per quality-adjusted life year (QALY) by deriving QALYs 
using utility values from the existing medical literature for health states described by the K-
BILD or the St George’s Respiratory Questionnaire (SGRQ), another secondary outcome 
measure [1]. However, appropriate HRQoL data in ILD patients on which to base an estimate 
of QALY gain are not available. Further research to derive a preference-based utility index 
for the K-BILD instrument is required to support accurate assessment of the benefits of 
treatment targeting HRQoL in ILD. Moreover, future trials should consider collecting a 
preference-based measure of health (such as the EQ-5D-5L) as an outcome[8, 9]. 
Nevertheless, despite these limitations, this study is the first to provide an indication of the 
cost-effectiveness of AO for improving HRQoL outcomes in ILD. Further evidence for the 
long-term effectiveness of AO, conversion of HRQoL outcomes in ILD to QALYs, and 
societal willingness to pay for HRQoL improvements are required to ensure the benefits of 
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